Anupam Rasayan India Ltd

- No significant new CAPEX planned for next year, so no immediate need for fresh fundraising. - Working capital currently high but expected to be released over the next 2 years. - Additional working capital for increased sales anticipated to be funded by release of existing working capital, minimizing need for external debt. - No mention of new equity fundraising in the call. - Overall, management does not foresee the need for significant external debt or fundraising in the near term based on current growth and CAPEX plans.

- As of June 30, 2024, Anupam Rasayan has utilized Rs. 530 crores out of the planned Rs. 670 crores CAPEX, with the balance to be incurred in upcoming quarters. - The current Rs. 670 crores CAPEX is at the final stages and expected to be completed this fiscal year. - No significant new CAPEX is planned for the next fiscal year as existing CAPEX and capacity are sufficient for near to medium-term growth. - Minor investments are anticipated in renewable energy (wind and solar) and some plant repurposing. - Strategic focus includes investment in sustainability, such as a Rs. 59 crores hybrid solar-wind power plant (9.6 MW capacity) aimed at reducing energy costs and achieving energy net zero by 2027. - Investment in Tanfac expansion supports fluorination raw material supply security without requirement for immediate further capacity expansion.

- Revenue expected to be equal or higher than last year with marginal growth, driven by strong resurgence in Agro segment in the latter half of the year. - Rs. 80 to 100 crores of deferment in demand expected to be recouped by year-end, largely from Agri portfolio. - New LOIs and contracts contributing about 20%-25% of this year's revenue with significant ramp-up expected in next 2 years. - Additional revenue of roughly Rs. 200 crores estimated annually over the next two years from new LOIs/contracts. - Polymer and Pharma segments growing strongly, with fluorinated products expected to form 30%-35% of revenue by FY27. - Investment in capacity expansion (Rs. 670 crores CAPEX) set to yield incremental revenue of Rs. 1,100 to 1,200 crores eventually. - Total revenue target around Rs. 2,000 to 3,000 crores in medium term. - Working capital expected to stabilize and support growth without significant new external debt.

- Revenue growth is expected to be marginally positive for FY25, with recovery in the agri segment in H2 FY25 helping recoup deferred demand of Rs. 80-100 crores. - New capacity commissioning and LOIs/contracts contribution projected to add around Rs. 250 crores in revenue this year, with further additions of ~Rs. 200 crores annually over next 2 years. - Pharma and Polymer segments are expected to grow, with Pharma contributing 20-25%, Polymer 15%, and Personal Care around 10-12% of revenue by FY27. - EBITDA margins expected to remain stable in the 25-28% range, supported by higher margin Polymer and fluorinated products. - ROCE anticipated to improve driven by CAPEX generating asset turn of ~1.5x and margin expansion. - Working capital optimization over next 2 years expected to reduce external debt needs, aiding profitability. - EPS expected to improve gradually aligned with revenue growth, margin expansion, and capacity ramp-up through FY27.

- The company expects revenue growth driven by new LOIs (Letters of Intent) and contracts, with about 20%-25% of this year's revenue coming from LOIs/contracts commercialized over the last 1-2 years. - For FY25, new LOIs and contracts are estimated to contribute around Rs. 250 crores, largely back-ended into the second half of the year. - Over FY26 and FY27, the company expects to add roughly Rs. 200 crores additional revenue each year from new LOIs and contracts. - The management indicates confidence in achieving these targets despite agrochemical segment headwinds. - The order book includes long-term contracts, especially from Pharma and Polymer segments, supported by fluorination chemistry expansion. - No specific total order book value was disclosed, but growth projections imply a strong, growing pipeline from recent commercializations and contracts.